Status:

UNKNOWN

Safety and Efficacy of Metformin for Treatment of Cytopenia in Children and Adolescents With Fanconi Anemia

Lead Sponsor:

Ain Shams University

Conditions:

Fanconi Anemia

Eligibility:

All Genders

5-18 years

Phase:

PHASE3

Brief Summary

Prospective interventional open-label non-randomized controlled trial to assess safety and efficacy of metformin in treating cytopenia in children and adolescents with Fanconi Anemia.

Detailed Description

Fanconi anemia (FA) is a genetic disease characterized by bone marrow failure, cancer susceptibility, and developmental abnormalities. Allogeneic hematopoietic stem cell transplantation offers curativ...

Eligibility Criteria

Inclusion

  • Age: 5 to 18 years
  • Patients who are diagnosed with Fanconi anemia based on clinical features and confirmed by increased chromosomal breakage on diepoxybutane (DEB) stress testing.
  • Presence of cytopenia (at least one of the following: hemoglobin (Hb) \< 10 g/dL, platelet count \< 100 x 109/L, or an absolute neutrophil count (ANC) \< 1.0 x 109/L
  • Patients receiving other therapies e.g., androgens are eligible for enrollment after a one-month washout period before the start of metformin.

Exclusion

  • Patients who underwent bone marrow transplantation.
  • Patients with evidence of myelodysplasia, leukemia, or other concurrent malignancy.
  • Patients who have a history of allergic reactions to metformin or similar compounds.
  • Patients with a history of symptomatic hypoglycemia over the past year or hypoglycemia \< 50 mg/dL on screening and baseline laboratory assessments.
  • Patients with type 1 diabetes mellitus.
  • Patients with vitamin B12 deficiency.
  • Patients with Glucose-6-Phosphate Dehydrogenase deficiency.
  • Patients with abnormal Kidney function tests including serum creatinine, elevated liver function tests including live enzymes (ALT or AST \> 135 U/L, total bilirubin \> 1.5 x upper limit of normal for age, and/or patients with metabolic acidosis (bicarbonate \< 17 meq/L on venous blood gases).

Key Trial Info

Start Date :

October 5 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2025

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06519786

Start Date

October 5 2022

End Date

March 1 2025

Last Update

July 25 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

University of Alexandria

Alexandria, Egypt

2

Ain Shams University

Cairo, Egypt, 11566

Safety and Efficacy of Metformin for Treatment of Cytopenia in Children and Adolescents With Fanconi Anemia | DecenTrialz